Stock Price Prediction

Viking Therapeutics (VKTX) is viewed bullishly due to its promising weight-loss drug pipeline, including Phase 2 and Phase 3 trials, with analysts setting an average price target of $112, reflecting a 225% upside from its current price of $34.41. The company is also considered a potential acquisition target, which could further boost its valuation. Strong analyst consensus (14 Buy ratings) and its competitive position in the GLP-1/GIP market support the bullish outlook.

VKTX stock is currently trading at $34.41, and the bear's view is centered on its lack of profitability and recent underperformance. The company has posted consistent losses, with an expected EPS of -$0.27 in the upcoming earnings, reflecting an 8% year-over-year decline. Additionally, the stock has dropped 22.85% in the past month, underperforming both the sector and broader market, signaling weak momentum and investor sentiment.